Strides Pharma Science Q4FY22 consolidated PAT at Rs. 29.21 Cr
The company has posted net loss of Rs. 460.21 crores for the Financial Year ended March 31, 2022.
The company has posted net loss of Rs. 460.21 crores for the Financial Year ended March 31, 2022.
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
He will be stationed at the company HQ in Bengaluru, India
The company has now received the renewed GMP (Good Manufacturing Practices) certificate thereby confirming the successful closure of the inspection
Mucormycosis drug AmphoTLC will be imported from Taiwan by Stelis Biopharma Private Limited (Stelis), the biotech arm of Strides group, and will be launched and distributed in India immediately by Strides
Strides Pharma Science Limited is pleased to announce that Aditya Puri joins the Strides Group as an Advisor and also will be a Director of its associate Company, Stelis Biopharma.
Subscribe To Our Newsletter & Stay Updated